Flaten, Gøril Eide

Permeabilitet over biologiske barrierer.
Snurr film til høyre for mer informasjon.

The phospholipid vesicle-based permeation assay (PVPA)

Liposomer som legemiddelbærer

Liposomer som modellsystem for celler og
bakterier i interaksjonsstudier

Delivery av lipofile virkestoff

Delivery of liposome-membrane associated anticancer agents to solid tumors exemplified by Camptothecin liposomes

A permeation model for damaged skin: Development of the Phospholipid Vesicular Based Permeation Model for New Applications

Estimation of intestinal absorption by use of the Phospholipid Vesicle-Based Permeation Assay (PVPA)

 
Publikasjonsliste

Cand.Pharm. avhandling
Incorporation of Camptothecin in liposomes, metod development and incorporation efficacy screening using different liposome formulations (June 2003)

PhD avhandling
The Phospholipid Vesicle-Based Barrier: A Novel Method for Passive Drug Permeability Screening (June 2007)

Publikasjoner i internasjonale peer-reviewed journaler

• 1) A.M. Sætern, G.E. Flaten, M. Brandl
  A method to determine the incorporation capacity of Camptothecin in liposomes
  AAPS PharmSciTech 5 (3) article 40 (2004)
• 2) G. E. Flaten, A.B. Dhanikula, K. Luthman, M.Brandl
  Drug permeability across a phospholipid vesicle barrier: a novel approach for studying passive diffusion, Eur. J. Pharm. Sci. 27, 80-90 (2006).
• 3) G. E. Flaten, H. Bunjes, K. Luthman, M. Brandl
  Drug permeability across a phospholipids vesicle-based barrier: 2. Characterization of barrier structure, storage stability and stability towards pH changes, Eur. J. Pharm. Sci. 28, 336-343 (2006).
• 4) G.E Flaten, M.L. Skar, K. Luthman, M. Brandl
  Drug permeability across a phospholipid vesicle-based barrier: 3. Characterization of drug-membrane interactions and the effect of agitation on barrier integrity and on the permeability, Eur. J. Pharm. Sci. 30, 324-332 (2007)
• 5) G. E. Flaten, K. Luthman, T. Vasskog, M. Brandl 
  Drug permeability across a phospholipid vesicle-based barrier: 4. The effect of tensides, co-solvent and pH changes on barrier integrity and on drug permeability, Eur. J. Pharm. Sci. 34, 173-180 (2008)
• 6) M. Brandl, G.E. Flaten and A. Bauer-Brandl, Passive Diffusion Across Membranes, Wiley Encyclopedia of Chemical Biology (2009)
• 7) G. E. Flaten, O. Awoyemi, K. Luthman, M. Brandl, U. Massing
  The phospholipid vesicle-based permeability assay: 5. Development towards an automated procedure for high throughput permeability screening, JALA, 14, 12-21 (2009)
• 8) J. Svenson,  R. Karstad, G. E. Flaten, B. Brandsdal, M. Brandl, J. S. Svendsen
  Altered activity and physico-chemical properties of short cationic antimicrobial peptides by incorporation of arginine analogs, Mol. Pharm, vol 6, no 3, 996-1005 (2009)
• 9) J.Kanzer, I. Tho, G.E. Flaten, M. Maegerlein, P. Hoelig, G. Fricker, M. Brandl
  In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid veicle-based barrier, Journal of Pharmacy and Pharmacology (2010), 62: 1591–1598
• 10) T.Hansen, D.Ausbacher, G. E. Flaten, M. Havelkova, and M. B. Strøm
  Synthesis of cationic antimicrobial β^2,2-amino acid derivatives with potential for oral administration, J Med Chem (2011) , 54 (3), 858–868
• 11) G.E. Flaten, K. Gabor, W. Stensen, G. Isaksen, R. Karstad, J.S. Svendsen, H. Daniel, and J.Svenson
  In vitro characterisation of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides, J Med Chem (2011) 54(7), 2422-2432
• 12) S.M. Fischer, G. E. Flaten, E. Hagesæther, G. Fricker, M. Brandl
  In Vitro Permeability of Poorly Water Soluble Drugs in the Phospholipid Vesicle-Based Permeation Assay (PVPA): The Influence of Non-Ionic Surfactants,  J Pharm Pharmacol (2011), 63, 1022–1030
• 13) J. Isaksson, B.O. Brandsdal, M. Engqvist, G. E. Flaten, J .S. Svendsen and W. Stensen
  A Synthetic Antimicrobial Peptidomimetic (LTX 109): Stereochemical Impact on Membrane Disruption, J Med Chem (2011) 54, 5786-5795
• 14) V. Tørfoss, J. Isaksson, D, Ausbacher, B.O. Brandsdal, G. E. Flaten, T. Anderssen,  C. de A. Cavalcanti-Jacobsen, M. Havelkova, L. T. Nguyen,  H. J. Vogel,M. B. Strøm Improved anticancer potency by head-to-tail cyclisation of short cationic anticancer peptides containing a lipophilic ß^2,2-amino acid, Journal of Peptide Science (2012), 18(10), 609-619
• 15) Flaten, G.E.; Chang, T.T.; Phillips, W; Brandl, M.; Bao, A. and Goins, B
  Liposomal Formulations of Poorly Soluble Camptothecin -Drug Retention and Biodistribution, Journal of Liposome Research (2012), early online  
• 16) Engesland, A.; Skar, M.; Hansen, T.; Skalko-Basnet, N.; Flaten, G. E. (2013)
  New Applications of PVPA: Permeation Model Mimicking Skin Barrier, Journal of Pharmaceutical Sciences, 102:1588-1600
• 17) Whitaker, RD.; Ingebrigsten, SG; Naderkhani, E; Skar, M L; Flaten, GE (2013)
  Investigation of parameters influencing incorporation, retention and cellular cytotoxicity in liposomal formulations of poorly soluble camptothecin, Journal of Liposome Research, accepted

Publikasjoner i andre journaler

• 1) G.E. Flaten. Legemidlers permeabilitet over en liposombasert barriere: en ny in vitro metode for å studere passiv diffusjon. Norsk Farmasøytisk Tidsskrift, januar 2006
• 2) G.E. Flaten. Legemidlers permeabilitet over en liposombasert barriere: en ny metode for å studere passiv diffusjon. Norsk Farmasøytisk Tidsskrift, desember 2007
• 3) G.E. Flaten, K. Luthman, and M. Brandl
  The Phospholipid Vesicle-Based Barrier for Screening of the Oral Absorption Properties of Drug Candidates," CRS Newsletter 28 (2) (2011) 20-21

Abstracts

• 1) G.E. Flaten, A.M. Sætern, M. Brandl
  Camptothecin-Lactone Incorporation in Liposomes - A Phase Solubility Study. International Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, March 27^th- 30^th 2004, Nurnberg, Germany
• 2) G.E. Flaten, A B Dhanikula, K Luthman, M Brandl
  A new approach for measuring drug permeability across phospholipid membranes, The Midnight Sun Meeting on Drug Transport and Drug Delivery, July 1^st-3^rd 2004, Tromsø, Norway
• 3) A.M. Sætern, B. Sveinbjørnsson, G.E. Flaten, M. Brandl
  Camptothecin-in-liposomes: Incorporation capacity and in vitro cytotoxicity. The Midnight Sun Meeting on Drug Transport and Drug Delivery, 1^st-3^rd of July 2004, Tromsø, Norway
• 4) A.M. Sætern, G.E. Flaten, M. Brandl
  Incorporation Efficacy of Camptothecin into Liposomes 2004 AAPS Annuel Meeting and Exposition, November 7^th 2004, Denver, USA
• 5) G.E. Flaten, K Luthman, A B Dhanikula, M Brandl
  The phospholipid vesicle based membrane, a novel model for studying passive drug permeability, PharmSciFair July 12^th to 19^th, 2005, Nice, France
• 6) G.E. Flaten, K. Luthman, M. Brandl
  Legemidlers permeabilitet over en liposombasert barriere: en ny metode for å studere passiv diffusjon, Norsk Farmaceutisk Forening, Farmasidagene 2005, October 27^th-29^th 2005, Oslo, Norway
• 7) G.E. Flaten, B.A. Dhanikula, K. Luthman, M. Brandl
  The Phospholipid Vesicle Based Barrier: A Novel in vitro Model for Studying Passive Drug Permeability. EUFEPS/AAPS Conference on Optimisation of Drug-Like Properties of Leads in Discovery: Fine-Tuning the Physchem-Biopharmaceutical-ADME-Tox Profile, March 2^nd-3^rd 2006, Zürich, Switzerland
• 8) G.E. Flaten, B.A. Dhanikula, K. Luthman, M. Brandl
  The Phospholipid Vesicle Based Membrane: A Novel in vitro Model for Studying Passive Drug Permeability. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, March 2006, Geneva
• 9) G. E. Flaten, A.B. Dhanikula, K. Luthman, M. Brandl
  A Novel in vitro Model for Studying Passive Drug Permeability / Absorbability: The Phospholipid Vesicle-Based Membrane
  Annual Meeting of the Controlled Release Society, July 22^nd-26^th 2006, Vienna, Austria
• 10) A. M. S. Holsæter, G.E. Flaten, M. Brandl
  Solubilisation of Poorly Soluble Drug Compounds by Liposomes: An Approach to Quantify the Drug Incorporation Capacity of Liposomes
  Annual Meeting of the Controlled Release Society, July 22^nd-26^th 2006, Vienna, Austria
• 11) G.E. Flaten, M.L. Skar, K. Luthman, M. Brandl 
  The phospholipid vesicle based barrier; a model for drug permeability screening. Pre-Satellite Meeting of the 3^rd Pharmaceutical Sciences World Congress for and by PhD Students and Young PostDocs, April 20^th - 21^th 2007, Amsterdam, The Netherlands
• 12) G.E. Flaten, H. Bunjes, K. Luthman, M. Brandl
  Drug permeability across a phospholipid vesicle based barrier: barrier structure characterization and effect of agitation on barrier integrity and drug permeability. Annual Meeting of the Controlled Release Society, July 7^th-11^th 2007,Long Beach CA, USA
• 13) G.E. Flaten, K. Luthman, M. Brandl
  Virkestoffers permeabilitet over en liposombasert barriere: en ny metode for å studere passiv diffusjon, Norsk Farmaceutisk Forening, Farmasidagene 2007, October 25^th-27^th 2007, Oslo
• 14) G.E. Flaten, K. Luthman, T. Vasskog, M. Brandl
  The phospholipid vesicle-based barrier: Effect of solubility enhancing agents and pH changes on barrier integrity and on drug permeability, 6^th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, April 7^th-11^th, 2008, Barcelona, Spain
• 15) G.E. Flaten, K. Luthman, T. Vasskog, M. Brandl
  The phospholipid vesicle-based barrier: Effect of pH changes, tensides and co-solvents on barrier integrity and on drug permeability. The 2^nd Midnight Sun Meeting on Drug Transport and Delivery, April 25^th-27^th, 2008, Tromsø, Norway
• 16) G. E. Flaten, O. Awoyemi, K. Luthman, M. Brandl, U. Massing
  Development towards an automated drug permeability assay based on immobilized phospholipid vesicles. AAPS 2008, November 16^th-21^th 2008, Atlanta, USA
• 17) G.E. Flaten, K. Luthman, T. Vasskog, M. Brandl
  The phospholipid vesicle-based barrier: Effect of solubility enhancing agents and pH changes on barrier integrity and on drug permeability, AAPS 2008, November 16^th-21^th 2008, Atlanta, USA
• 18) S. M. Fischer, G. E. Flaten, K. Luthmann, G. Fricker, M. Brandl
  Oral bioavailability screening: Comparison of the Phospholipid vesicle-based permeation barrier with the Caco-2 cell model. Phospholipid Symposium, March 2009 , Heidelberg, Germany
• 19) S. M. Fischer, G.E. Flaten, M. Brandl, G. Fricker
  The effects of various non-ionic surfactants on the permeation of nadolol across Caco-2 cell monolayers and Phospholipid vesicle-based barriers. AAPS Annuel Meeting and Exposition, November 2009, Los Angeles, USA
• 20) S. M. Fischer, G.E. Flaten, G. Fricker,  M. Brandl,
  Permeation Studies using the Phospholipid Vesicle-Based Model: Impact of Surfactants, Midsummer Meeting on Drug Transport and Delivery,June 2010, Gothenburg, Sweden 
• 21) J. Isaksson, G.E. Flaten, B. Brandsdal, J.S. Svendsen, Studies of small synthetic anti-microbial peptides by NMR and molecular modeling, EUROMAR July 2010, Florence, Italy
• 22) G.E. Flaten, O. Awoyemi, U. Massing, K. Luthman, M. Brandl
  The Phospholipid Vesicle-Based Barrier: A Tool For In Vitro Drug Permeability Screening, Annual Meeting of the Controlled Release Society, July 10^th-14^th 2010,Portland, OR, USA
• 23) S. M. Fischer, G. E. Flaten, E. Hagesæther, S. T. Buckley, G. Fricker, M. Brandl
  The influence of poloxamer 188 on drug permeability across caco-2 cellmonolayers and the PVPA-barrier,  Symposium of the Phospholipid Research Center, September12^th-13^th 2011, Heidelberg, Germany
• 24)  G. E. Flaten, S. M. Fischer, J. Kanzer, K. Luthman, M. Brandl
  The phospholipid vesicle-based permeation assay (PVPA) for screening of the oral absorption properties of drug candidates, AAPS Annuel Meeting and Exposition, October 2011, Washington DC, USA
• 25) E. Naderkhani, A. Engesland, A. Ryzhakov, G.E. Flaten
  The phospholipid vesicle-based permeation assay (PVPA) for screening of drug permeabilityCRC Nordic Chapter, June 2012, Reykjavik, Iceland
• 26) E. Naderkhani, N. Skalko-Basnet, G. E. Flaten
  Improved prediction of intestinal permeability using the phospholipid vesicle-based permeation assay (PVPA), 9th Central European Symposium on Pharmaceutical Technology, September 2012, Dubrovnik, Croatia 
• 27) A. Engesland, M. Skar, T. Hansen, N. Skalko-Basnet,G. E. Flaten
  Development of an artificial in vitro permeation model for the skin, 9th Central European Symposium on Pharmaceutical Technology, September 2012, Dubrovnik, Croatia